As of 2026-01-07, the EV/EBITDA ratio of Alpine Immune Sciences Inc (ALPN) is -87.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ALPN's latest enterprise value is 4,423.93 mil USD. ALPN's TTM EBITDA according to its financial statements is -50.34 mil USD. Dividing these 2 quantities gives us the above ALPN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.9x - 15.6x | 15.2x |
| Forward P/E multiples | 22.0x - 22.4x | 22.2x |
| Fair Price | (15.66) - (10.97) | (13.26) |
| Upside | -124.1% - -116.9% | -120.4% |
| Date | EV/EBITDA |